The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

In this piece, we will look at the stocks Jim Cramer discussed.

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic ...

More gains for Nvidia, Amazon and other AI superstars propped up Wall Street on Monday. The S&P 500 rose 0.2% and pulled closer to its all-time high set last week, even though the majority of stocks ...